Artisan Partners Limited Partnership Makes New $21.34 Million Investment in LivaNova PLC (NASDAQ:LIVN)

Artisan Partners Limited Partnership acquired a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 460,802 shares of the company's stock, valued at approximately $21,340,000. Artisan Partners Limited Partnership owned 0.85% of LivaNova as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Point72 Asset Management L.P. boosted its holdings in LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Vanguard Group Inc. raised its position in shares of LivaNova by 12.7% in the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after purchasing an additional 265,291 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of LivaNova during the 4th quarter valued at approximately $9,645,000. Point72 DIFC Ltd grew its position in shares of LivaNova by 75,799.6% during the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company's stock worth $9,531,000 after buying an additional 181,161 shares in the last quarter. Finally, Ruffer LLP bought a new stake in shares of LivaNova in the fourth quarter worth $7,982,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Up 0.6 %

LIVN traded up $0.22 on Wednesday, reaching $39.25. 99,237 shares of the company traded hands, compared to its average volume of 608,337. LivaNova PLC has a 52-week low of $36.85 and a 52-week high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.13 billion, a price-to-earnings ratio of 93.24 and a beta of 1.10. The stock's 50 day moving average price is $44.12 and its 200-day moving average price is $48.35.

Remove Ads

Analyst Ratings Changes

Several brokerages have recently commented on LIVN. The Goldman Sachs Group reduced their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a report on Monday, March 17th. Barclays reduced their price objective on LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a research note on Friday, March 7th. Finally, Mizuho decreased their price objective on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.